Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + TAS-102 in 3rd-line RASwt mCRC
NCT05155124Phase 1Unknown
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab in metastatic colorectal cancer (mCRC). Primary endpoint: Incidence of Dose-Limiting Toxicity at 18 months. Status: unknown.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05155124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155124.